JP Morgan Chase
MGX icon

JP Morgan Chase’s Metagenomi Therapeutics MGX Stock Holding History

JP Morgan Chase’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.02K Hold
1,596
– – ﹤0.01% 7012
2025
Q4 		$2.58K Sell
1,596
-60,963
-97% -$132K ﹤0.01% 6904
2025
Q3 		$148K Buy
62,559
+61,089
+4,156% +$124K ﹤0.01% 5681
2025
Q2 		$2.18K Sell
1,470
-13,118
-90% -$20.5K ﹤0.01% 6527
2025
Q1 		$19.8K Sell
14,588
-58,443
-80% -$139K ﹤0.01% 6153
2024
Q4 		$264K Buy
73,031
+65,020
+812% +$157K ﹤0.01% 5361
2024
Q3 		$17.4K Buy
8,011
+5,322
+198% +$18.5K ﹤0.01% 6263
2024
Q2 		$11K Sell
2,689
-11,058
-80% -$76K ﹤0.01% 6243
2024
Q1 		$145K Buy
+13,747
New +$158K ﹤0.01% 5512

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase's MGX Position: Q1 2026 in Review

JP Morgan Chase held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 1,596 shares worth $2.02K. The position accounts for ﹤0.01% of the portfolio, ranked #7012.

JP Morgan Chase first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $264K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • JP Morgan Chase held 1,596 shares of Metagenomi Therapeutics worth $2.02K as of Q1 2026.
  • JP Morgan Chase left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7012 holding.
  • JP Morgan Chase first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • JP Morgan Chase's Metagenomi Therapeutics position peaked at $264K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.